This upper/yellow main patient cluster (i.e., patients 1–10 in Table S1) had a significantly higher frequency of patients with AML following previous myelodysplastic syndrome or chronic myeloproliferative neoplasia (Fisher’s exact test, p = 0.0165) than the other patients (Patients 11–41), but these two main clusters/patient subsets did not differ with regard to patient age, sex, AML cell differentiation (morphology/FAB, expression of the CD34 stem cell marker) or genetic abnormalities (karyotype, FLT3/NPM1 abnormalities). This evidence concerns the gene FLT3 and myelodysplastic syndrome.